A set of ~800 largely isogenic deficiency stocks created by FLP-induced recombination between FRT-carrying transgenic insertions; molecularly defined deletion endpoints correspond to initial location of the progenitor insertions. Designed to fill gaps in deletion coverage and breakpoint placement; also used to replace older available deficiencies that have not been molecularly mapped.
Exelixis, Inc. determined the insertion site of the progenitor P{XP}d03477 to be at Release 3 genomic coordinate 13860811 on chromosome arm 2L. This corresponds to Release 5 coordinate 2L:13878659 . The insertion site of the progenitor PBac{WH}f02709 is at Release 5 genomic coordinate 13421556 on arm 2L. Consequently, the breakpoints of Df(2L)BSC812 predicted from the Release 5 genomic coordinates of the progenitor insertion sites are 2L:13421556 ;13878659 and the cytological breakpoints predicted from these coordinates are 34B11;34E1.